Morgan Stanley Rates IQVIA (IQV) hold, $200 Price Target

Morgan Stanley lowered its rating on IQVIA Holdings to hold with a $200 price target, a 19.18% upside from the current price.

By TradeTexts Research Desk · Published Jun 17, 2026, 9:00 AM EDT · Updated Jun 23, 2026, 12:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley rated IQVIA Holdings Inc. ($IQV) "hold" with a $200 price target on June 17, 2026.

Since the rating, $IQV is up 8.8% after 1 week, up 20.9% after 1 month and up 56.4% to date (from the $170.67 close on Jun 17, 2026).

IQV IQVIA Holdings Inc.

$266.90 +18.43% year to date

Daily close · Oct 16, 2026

Key Points

Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings to a hold rating with a $200 price target on June 17, 2026.
Morgan Stanley's $200 price target implies 19.18% upside from IQVIA Holdings Inc.'s ($IQV) current $167.81 share price.
IQVIA Holdings, trading at $179.17, has a market cap of $29.9 billion and a P/E ratio of 22.26, indicating its valuation metrics.
Insiders like John Danhakl and Colleen Goggins have recently bought shares, while peers like BlackRock increased their holdings.

Get $IQV trade alerts by text

We text you when insiders, Congress or big funds trade $IQV. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated IQVIA Holdings Inc. alert may contain errors. Disclosures

On June 17, 2026, Morgan Stanley's analyst Kallum Titchmarsh downgraded IQVIA Holdings Inc. (NYSE:IQV) to a hold rating. The analyst set a price target of $200 for the healthcare and diagnostics company.

Other Institutional Activity in IQVIA Holdings

Several institutional investors have been active in IQVIA Holdings recently. BlackRock, Inc. increased its holdings by 867,371 shares, ending with 15,027,444 shares valued at approximately $2.56 billion. Harris Associates L.P. also added 863,557 shares, bringing its total to 12,183,275 shares worth about $2.08 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both reported holding 11,026,983 and 7,576,001 shares, respectively, without prior holdings data. State Street Corp added 30,050 shares, totaling 7,476,962 shares valued at $1.28 billion. JPMorgan Chase & Co significantly increased its stake by 1,608,090 shares, reaching a total of 5,407,690 shares valued at $898.5 million.

IQVIA Holdings Inc. Stock Down 37.0%

Shares of IQVIA Holdings are trading at $179.17. The company has a market capitalization of $29.9 billion and a P/E ratio of 22.26, indicating its current valuation. IQVIA's stock has traded between $153.01 and $247.05 over the past 52 weeks. The 50-day moving average is $173.36, while the 200-day moving average is $195.50. The company has a beta of 1.215, suggesting moderate volatility relative to the market.

12-month forecast

$IQV price target

IQVIA Holdings Inc. daily closes and this analyst's $200 target. Not advice.

Recent Earnings

IQVIA Holdings reported revenue of $16.63 billion, showing a growth of 8.4%. The company's earnings per share (EPS) stood at $8.05, with a net margin of 8.33% and a return on equity (ROE) of 22.49%. The next earnings report is expected on July 21, 2026.

Insider Buying and Selling at IQVIA Holdings Inc.

Several insiders have recently purchased shares of IQVIA Holdings. On May 7, 2026, John Danhakl and Colleen Goggins each bought 185 and 214 shares, respectively, at an average price of $178.64. Jim Fasano acquired 228 shares on the same date. Earlier, on April 23, 2026, William Kaelin Jr. and Jim Fasano each bought 1,571 shares at $160.68.

Analysts Set New Price Targets

On June 17, 2026, Morgan Stanley downgraded its rating on IQVIA Holdings to hold, setting a price target of $200. Other analysts have also weighed in recently. On April 8, 2026, Evercore ISI Group maintained a buy rating with a $185 target. TD Cowen upgraded the stock to buy with a $213 target on March 9, 2026. RBC Capital initiated coverage with a buy rating and a $221 target on March 3, 2026. The consensus rating remains strong buy, with an average target price of $226.95 across 19 analyst opinions.

About IQVIA Holdings

IQVIA Holdings Inc. is a leading provider of clinical research services and healthcare analytics. Headquartered in Durham, North Carolina, the company operates globally, offering solutions in technology and analytics, research and development, and contract sales. Under the leadership of CEO Ari Bousbib, IQVIA serves the life sciences and healthcare industries, providing insights and services that enhance healthcare delivery and patient outcomes.

Bottom Line

Morgan Stanley's downgrade of IQVIA Holdings to a hold rating reflects a cautious stance on the stock, with a price target of $200. The company remains a significant player in the healthcare analytics and research sector, with a strong market presence and robust financial performance. Investors and analysts continue to monitor IQVIA's strategic moves and market dynamics, keeping a close eye on its upcoming earnings report on July 21, 2026.